EC Number |
Inhibitors |
Structure |
---|
3.2.1.207 | (1S,2R,3R,4R)-4-(hydroxymethyl)-5-[5-([(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydro-2H-chromen-6-yl]oxy)pentyl]cyclohexane-1,2,3-triol |
inhibitor affects only myeloid lineage immune cells |
|
3.2.1.207 | (1S,2S,3R,6S)-6-[[(2R,3S,4S,5R,6S)-3,5-dihydroxy-2-(hydroxymethyl)-6-methoxyoxan-4-yl]amino]-4-(hydroxymethyl)cyclohex-4-ene-1,2,3-triol |
valienamine-derived N1->3-linked pseudosaccharide |
|
3.2.1.207 | (1S,2S,3R,6S)-6-[[(2R,3S,4S,5S,6S)-3,5-dihydroxy-2-(hydroxymethyl)-6-methoxyoxan-4-yl]amino]-4-(hydroxymethyl)cyclohex-4-ene-1,2,3-triol |
valienamine-derived N1->3-linked pseudosaccharide |
|
3.2.1.207 | 1,4-dideoxy-1,4-imino-D-arabinitol |
- |
|
3.2.1.207 | 1-deoxynojirimycin |
- |
|
3.2.1.207 | 1-deoxynojirimycin |
more specific inhibitor of alpha-glucosidase II than of alpha-glucosidase I |
|
3.2.1.207 | 1-deoxynojirimycin |
0.01 mM, 60% inhibition |
|
3.2.1.207 | 1-deoxynojirimycin |
0.1 mM, complete inhibition |
|
3.2.1.207 | 2,6-anhydro-1-benzamide-D-glycero-D-ido-heptitol |
- |
|
3.2.1.207 | 2,6-dideoxy-2,6-imino-7-O-(beta-D-glucopyranosyl)-D-glycero-L-glucoheptitol |
MDL |
|